GLA 27

nonreducing sugar part of lipid A analog with interferon-inducing, tumor necrosis factor-inducing, but not pyrogenic acitivity; structure given in first source

Also Known As:

2-deoxy-4-O-phosphono-3-O-tetradecanoyl-2-(3-tetradecanoyloxytetradecanamido)-D-glucose; 3-O-tetradecanoyl-2N-3-tetradecanoyloxytetradecanoyl-4-O-phosphonoglucosamine; GLA-27

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Infections 08/01/1990 - "aeruginosa infection and macrophage activation activity, GLA-60 and GLA-68, which carry a C14-O-(C14) group at the 3-O-position, expressed higher activities than GLA-27 and GLA-59, which carry the acyloxyacyl group at the 2-N-position. " 05/01/1988 - "Activities for enhancing nonspecific host resistance against microbial infections and growth inhibition against tumors by a lipid A-subunit analogue GLA-27 were investigated. " 01/01/1990 - "Enhancement of nonspecific resistance to microbial infections of synthetic lipid A-subunit analogues of GLA-27 modified at the C1 position of the glucosamine backbone."
2.	Shwartzman Phenomenon (Shwartzman Reaction) 05/01/1988 - "GLA-27 did not exhibit toxic activities such as pyrogenicity and Shwartzman reaction." 01/01/1988 - "Toxic manifestations such as pyrogenicity, local Schwartzman reaction and lethality were far less pronounced for GLA-27 and GLA-60 than for natural lipid A."
3.	Pseudomonas Infections 05/01/1988 - "GLA-27 also showed nonspecific protective activity against Pseudomonas aeruginosa infection at a dose of 30 micrograms/mouse, although the activity was far less than that induced by lipid A. "
4.	Neoplasms (Cancer) 05/01/1988 - "GLA-27, a 4-O-phosphono-D-glucosamine derivative with 2-N-3-tetradecanoyloxytetradecanoyl and 3-O-tetradecanoyl group, inhibited significantly the growth of solid-type tumors RL male 1 lymphoma and Meth A fibrosarcoma. " 05/01/1988 - "Activities for enhancing nonspecific host resistance against microbial infections and growth inhibition against tumors by a lipid A-subunit analogue GLA-27 were investigated. "
5.	Lymphoma (Lymphomas) 05/01/1988 - "In the case of RL male 1 lymphoma, 2.5 micrograms of GLA-27 was needed to exhibit the activity, while for Meth A fibrosarcoma, 250 micrograms of GLA-27 was needed. " 05/01/1988 - "GLA-27, a 4-O-phosphono-D-glucosamine derivative with 2-N-3-tetradecanoyloxytetradecanoyl and 3-O-tetradecanoyl group, inhibited significantly the growth of solid-type tumors RL male 1 lymphoma and Meth A fibrosarcoma. "

Related Drugs and Biologics

1.	Lipid A
2.	GLA 60
3.	Glucosamine (Dona)